SLC5A2 and heart failure: Despite a potential higher risk for SGLT2 inhibitors adverse effects in the context of acute illness and the resulting current advise against using them in COVID-19 patients, as recently emphasized [112], they have a favorable efficacy profile in preserving renal function, decreasing the impact of heart failure and increasing the survival of patients with risk factors for severe COVID-19.